NanoViricides (NNVC)
XASE:NNVC
NNVC Stock Chart & Stats
$1.13
-$0.10(-6.54%)
At close: 4:00 PM EST
$1.13
-$0.10(-6.54%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous CloseN/A
Volume409.80K
Average Volume (3M)143.34K
Market Cap
$21.22M
Enterprise Value-$5.15T
Total Cash (Recent Filing)$5.15T
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding21,595,000
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap-242.71K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.88M
Enterprise Value/Ebitda667.80K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformThe proprietary nanoviricide platform targets viruses by mimicking host-cell binding and disrupting particles. A platform approach supports multiple discovery programs and durable IP, creating pipeline optionality and potential compoundable value beyond any single candidate.
Low LeverageNear-zero debt materially lowers solvency risk and preserves strategic flexibility for a cash-burning biotech. This structural strength allows more options for financing, partnerships, or staged spend without immediate bankruptcy risk, supporting operations over the medium term.
Clinical-stage + ManufacturingBeing clinical-stage with in-house manufacturing gives control over CMC, supply and timelines, reducing execution risk versus fully outsourced peers. Structural manufacturing capability supports scale-up, makes partnering/licensing more credible, and aids durable program advancement.
Bears Say
No RevenueThe company reports no revenue and sustained sizable net losses, leaving operations entirely dependent on external capital rather than commercial cash flows. This structural reliance on financing creates execution and continuity risk over the coming months absent a commercial pivot.
Negative Cash GenerationOperating and free cash flows are persistently negative and roughly align with net losses, indicating real cash burn rather than non-cash charges. The lack of an improving cash-burn trend implies ongoing funding needs and heightened sensitivity to financing markets over the medium term.
Equity Erosion / Dilution RiskMaterial decline in shareholders' equity over several years reflects cumulative losses and prior financing; this eroded cushion increases the likelihood of further dilution or unfavorable financing terms. Reduced equity limits strategic flexibility and raises governance/ownership risks.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $21.22M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 224 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Overvalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 21,595,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoViricides
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Technical Analysis
Ownership Overview
―
Insiders
3.13% Mutual Funds
7.23% Other Institutional Investors
87.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---